N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 The Role of Skin Care Regimen in Skin Health
Itching · Xerosis
Primary: Change in Total Clinical Score (TCS) Between the Final Visit and Baseline — -4; -2 score on a scale
Phase 4 N=33 A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
Healthy
Primary: Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days — 0.1; 0.4 units on a scale
N/A N=132 A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
Skin Care
Primary: Change From Baseline in Corneometer Values at 8 Hours on Day 1 — 6.14; 2.63; 3.60 Arbitrary Corneometer unit — p=0.0128
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 2 N=77 Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
Dermatitis, Seborrheic · Dry Skin; Eczema
Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001
N/A N=121 A Clinical Investigation With Epaderm® Cream
Eczema · Psoriasis · Dry Skin; Eczema
Primary: Number of Participants With Improved Skin Moisturization — 114 Participants
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
N/A N=90 A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin
Skin Care
Primary: Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use — 3; 0…
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
N/A N=99 Skin Care for Cancer Patients: A Product Satisfaction Survey
Skin Toxicity
Primary: Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash…
N/A N=60 Effectiveness of Using an Oil Bath Additive
Xerosis Cutis
Primary: Transepidermal Water Loss (TEWL) in g/m2/h at the Left Mid Volar Forearm — 10.0; 11.9 g/m2/h — p=0.002
N/A N=66 A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm
Skin Care
Primary: Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated Versus (vs.) Untreated Sites on the Forearm — -0.59; 0.79 gram…
Phase 2 N=310 Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
Eczema · Allergy Symptoms · Psoriasis
Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants
N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
N/A N=113 To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Skin Care
Primary: Frequency of Combined Dermatologist Score — 1; 1; 51; 55 Participants
N/A N=150 A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
Skin Care
Primary: Number of Participants Determined by a Dermatologist to Have a Clinically Relevant Positive Outcome for Cutaneous Irritation After 21 Days of Product Use — 1; 0; 0…
Phase 4 N=528 CeraVe Diabetes Mellitus
Diabetes Complications
Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
N/A N=24 Human Comedogenicity Test
Comedogenicity
Primary: Microcomedone Score of Follicular Biopsies — 0.84; 0.97 microcomedone score — p=0.274
Phase 4 N=21 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Investigator Global Assessment Scale for Severity of Facial Acne — 0; 0; 11; 9 Participants
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 3 N=47 Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24 — -1.8; -0.5 score on a scale
Phase 4 N=28 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted
Phase 4 N=50 A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
Acne Vulgaris
Primary: The Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment. — 131.27; 113.94 microSiemens (μS)…
N/A N=45 A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Cutaneous Tolerance Scores: Erythema — -0.07 Units on a scale
N/A N=82 Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure
Skin Care
Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334
N/A N=149 To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function
Dry Skin · Skin Care
Primary: Change From Baseline in Trans-epidermal Water Loss (TEWL) Following Application of Test Regimen on Face (Area 1 Compared to Area 2) at Day 29 — -5.077; -4.946; -3.692…